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BACKGROUND:  Malignant  triton  tumors  (MTT)  represent  a  rare  subset  of  tumors  with  rhabdomyoblastic
differentiation  within  the  heterogeneous  group  of malignant  peripheral  nerve  sheath  tumors  (MPNST).
CASE PRESENTATION:  Here,  we  report  on a case  of  a 25 year-old  male  with  a history  of  neuroﬁbromatosis
type  I  and  MTT  of the  mediastinal  wall  who  presented  in  our  clinic  with  a pelvic  tumor  and  multiple  hyper-
vascular  mesenteric  masses  and  underwent  resection.  Upon  resection,  histological  ﬁndings  revealed  an
MTT  of  the  omentum  and  an atypical  neuroﬁbroma  of  the  pelvis  with  focal  transitions  to a low-grade
MPNST.  The  patient  relapsed  just  one  month  later  and  died  3 months  after  the  surgery.
CONCLUSION:  Clinically,  MTTs  are  characterized  as  highly  aggressive  tumors  that are  fast-growing  and
prone to local  recurrence  and  distant  metastasis.  To  date,  there  is  no  treatment  consensus  available  yet
and  many  patients  succumb  to the  disease  shortly  after  diagnosis.  This  is because  the  pathogenesis  of  MTT
remains  unknown  and patients  with  MTT  are  often  diagnosed  at a late  stage  of disease.  Our  case  presents
valuable  teaching  points  in terms  of providing  a possible  progression  model  based  on  the coexistence  of
a low-grade  MPNST  and  MTT  in the context  of NF1  and an  atypical  neuroﬁbroma  in this  patient.  Close
monitoring  of patients  with  NF1  and  atypical  neuroﬁbromas  or  MPNST  might  therefore  help  to diagnose
MTT  at  an  earlier  stage.
©  2016  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Malignant triton tumor (MTT) is an extremely rare type of sar-
oma that arises from peripheral nerve sheaths. This tumor is
hought to originate from Schwann cells of peripheral nerves or
ithin existing neuroﬁbromas and is characterized by the coexis-
ence of malignant rhabdomyoblasts and malignant Schwann cells
19]. The ﬁrst description of MTT  dates back to 1932, when Mas-
on described rhabdomyosarcomatous elements within malignant
eripheral nerve sheath tumors (MPNST) in patients with neuroﬁ-
romatosis. To date, approximately 170 cases of MTT  have been
escribed in the literature of which more than 50% had previously
een diagnosed with neuroﬁbromatosis 1 (von Recklinghausen’s
isease, NF1) (Woodruff et al., 2000). We  report on a rare case of
Abbreviations: MTT, malignant triton tumor; MPNST, malignant peripheral
erve sheath tumor; NF1, neuroﬁbromatosis type 1.
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MTT  of the omentum in a patient with NF1 and a history of MTT  of
the mediastinal wall.
2. Case report
A 25 year-old man  with NF1 who had previously been diag-
nosed with MTT  was referred to the Heidelberg University Hospital
in October 2014. He had been diagnosed with atypical extrapleu-
ral neuroﬁbroma in 2010 and had undergone right posterolateral
thoracotomy with resection of the seventh to twelfth rib along
with partial resection of the right hemidiaphragm. Following this,
the patient had observed a growing mass of his right chest wall.
Surgical exploration in September 2014 revealed a 10 × 10 cm
measuring round mass that was inﬁltrating the adjacent muscu-
lar tissue. However, no organ inﬁltration could be observed. The
mass was  completely resected with partial resection of the 11th
and 12th ribs. Microscopic examination of this tumor revealed a
MTT  with complete negative margins (R0) and the patient was
referred to Heidelberg University Hospital for further oncologic
treatment. Upon presentation of the case to our tumor-board, the
patient underwent adjuvant radiotherapy in shrinking ﬁeld tech-
nique with 5 × 1.8 Gy/week up to 63.0 Gy from November until
December 2014. The patient presented in our Surgical Depart-
ment in January 2015 after a pelvic mass had been discovered
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. T2 abdominal and pelvic MRI  with contrast on Feburary 13th, 2015 revealed the previously known pelvic tumor (A) along with newly formed hypervascular mesenteric
masses  (B).
Fig. 2. Microscopically, the pelvic tumor was composed of spindle cells expressing the neurogenic differentiation marker S100 (A). The pelvic tumor did not show any
rhabdomyosarcomatous differentiation as indicated by absent Myogenin expression (C) and had a Ki67-proliferative index of 1–3% (E), in line with a low-grad MPNST.
Immunohistochemical stainings of the mesenteric nodules showed spindle cells without expression of S100 (B), however, with focally abundant expression of Myogenin (D)
and  a Ki67-proliferative index of 70–80% (F).
d
iFig. 3. Progression m
uring follow-up. Physical examination did not reveal any signif-
cant abnormalities. Laboratory ﬁndings were all within normalodel for MTT.
limits except for NSE, which was slightly elevated. Abdominal and
pelvic magnetic resonance imaging revealed a 7.0 × 6.5 cm pelvic
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ass along with previously unknown hypervascular mesenteric
asses and the patient was worked-up for exploratory laparo-
omy (Fig. 1). Upon laparotomy, approximately 8–10 omental
odules were discovered without evidence of intestinal or abdom-
nal wall manifestations of the disease. We  therefore decided
o perform an omentectomy. In line with preoperative ﬁndings,
nother mass could be palpated in the right lesser pelvis, which
acroscopically appeared to originate from the obturatory nerve.
y opening the nerve sheath, we could exstirpate the mass while
paring the nerve. Histopathological examination of the pelvic
ass revealed an atypical neuroﬁbroma with pluri- and multi-
ocal transitions to a low-grade MPNST. Immunohistochemically,
he spindle-shaped tumor cells homogenously expressed Protein
100 and p53 without evidence of expression of Desmin, Aktin,
aldesmon, Myogenin or CD34 and a Ki67-proliferative index
f 1–3% (Fig. 2). Histopathological examination of the mesen-
eric nodules revealed an MTT  characterized by an MPNST with
bundant rhabdomyosarcomatous differentiation. Immunohisto-
hemical staining showed homogenous expression of CD56 and
imentin with focal distribution of myogenin, desmin, aktin and
euroﬁlament expressing cells and a Ki67-proliferative index of
0–80%. Immunohistochemical stainings were negative for Protein
100, GFAP, Neuroﬁbromin, Synaptophysin, Caldesmon, CD34 and
D57 (Fig. 2). After surgical treatment, the patient was  discharged.
owever, one month later he relapsed with multiple abdominal
nd thoracic masses and died 3 months after the surgery.
. Discussion
constitute a heterogenous group of malignant tumors of
ctomesenchymal origin. They arise from major or minor periph-
ral nerve branches or from peripheral nerve ﬁber sheaths [1–3].
he confusing terminology that describes these tumors as malig-
ant schwannoma, malignant neurilemmoma, neuroﬁbrosarcoma
r neurogenic sarcoma has been replaced by the term MPNST that
as been coined for tumors of neurogenic origin and similar biolog-
cal behavior [4,5]. MPNST may  arise sporadically, however, 5–42%
f all MPNST are associated with NF1 and approximately 10% of
F1 patients develop MPNST [6–9]. NF1 is an autosomal domi-
ant inherited multisystem disorder that is clinically characterised
y light brown skin spots (café au lait spots), colored bumps on
he iris (Lisch nodules) and neuroﬁbromas and affects 1 in 3500
eople [10]. While MPNST can be histologically diverse, their clin-
cal behavior is often aggressive with a tendency to recur and to
etastasize. Large tumor size, association with NF1, truncal loca-
ion as well as a high grading and a mitotic index of greater than
/10 high-power ﬁelds have been identiﬁed as predictive factors
or a poorer prognosis [11,12]. The overall survival rate for MPNST
as been reported to be 34–44% with radical surgery continuing
o be the mainstay of current management owing to the limited
ensitivity toward both chemotherapy and radiation. Epitheloid as
ell as rhabdomyoblastic, cartilaginous, osseous differentiations
nd, rarely, smooth muscle, glandular or liposarcomatous compo-
ents can be observed in up to 15% of MPNST [13–15]. The most
ommon heterologous component in MPNST is rhabdomyoblastic
ifferentiation [16]. This differentiation pattern was ﬁrst reported
y Masson in 1932 and named “nerve rhabdomyoma”, and later
enamed by Woodruff as “malignant triton tumor” in 1973 [17].
4–69% of MTTs occur in association with NF1. The average age of
atients with MTT  is 31.7 without a gender difference. Clinically,
TTs are characterized by their aggressive behavior and a dismal
rognosis with a ﬁve-year survival rate of 12–26% [18]. Like MPNST,
TTs are insensitive to chemotherapy and radiation. While sev-
ral authors have reported that R0 resection followed by adjuvant
hemotherapy may  yield disease control, there is need for furtherPEN  ACCESS
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studies to ascertain the exact role of chemo- and radiotherapy. To
date, the pathogenesis of MTT  remains unknown. We  report here
the ﬁrst case of a low-grade MPNST and concomitant MTT  in the
context of NF1 and an atypical neuroﬁbroma. This unusual pre-
sentation of disease suggests that MTT, rather that representing a
distinct entity of cancer, are dedifferentiated MPNST that arise from
atypical neuroﬁbromas (Fig. 3). While further studies are needed to
validate our hypothesis, this case might provide grounds for active
surveillance of NF1 patients with a medical history of atypical neu-
roﬁbromas and/or MPNST. Furthermore, the aggressive course of
disease in the presented case with the occurrence of metastatic
lesions 4 months after complete resection gives rise to the ques-
tion if chemotherapy, albeit unproven in efﬁcacy, can eradicate
subclinical micrometastases.
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